Skip Navigation


JAC Advance Access originally published online on July 1, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/2/168    most recent
dkg309v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (40)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Davies, T. A.
Right arrow Articles by Evangelista, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, T. A.
Right arrow Articles by Evangelista, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 168-175
© 2003 The British Society for Antimicrobial Chemotherapy

Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998–2000)

Todd A. Davies1,*, Raul Goldschmidt1, Sharon Pfleger2, Mike Loeloff1, Karen Bush1, Daniel F. Sahm3 and Alan Evangelista2

1 Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Room B201C, 1000 Route 202, Raritan, NJ 08869; 2 Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ 08869; 3 Focus Technologies, Herndon, VA 20171, USA

Received 7 March 2003; returned 6 April 2003; revised 24 April 2003; accepted 29 April 2003

Objectives: To detect relatedness among 68 (0.5%) of 13 795 US clinical isolates of Streptococcus pneumoniae from the TRUST 3 (1998–1999) and TRUST 4 (1999–2000) surveillance studies that were resistant to levofloxacin (MIC >= 8 mg/L).

Methods: All levofloxacin-resistant isolates were analysed by broth microdilution reference method for susceptibility to four fluoroquinolones, DNA sequencing of quinolone resistance determining region (QRDR) of topoisomerase IV and DNA gyrase genes, serotyping, and pulsed-field gel electrophoresis (PFGE).

Results: All levofloxacin-resistant isolates were ciprofloxacin resistant (MIC >= 4 mg/L, FDA breakpoint) and non-susceptible to gatifloxacin (MIC >= 2 mg/L); 62 were non-susceptible to moxifloxacin (MIC >= 2 mg/L). Resistant isolates were in 48 (20%) of 238 institutions in 29 states. Three institutions had levofloxacin-resistant isolates in both surveillance studies. Among the resistant isolates were 17 serotypes and 48 different PFGE patterns. Fourteen isolates had PFGE patterns closely related to the Spain23F-1 clone; one strain had a PFGE pattern closely related to the French9V-3 clone. All levofloxacin-resistant isolates had two or more mutations within the QRDR of parC, parE, gyrA and gyrB.

Conclusions: US levofloxacin-resistant S. pneumoniae isolates were rare and most were unrelated with minimal clonal spread, and were associated with multiple QRDR mutations with extensive cross-resistance noted among fluoroquinolones.

Keywords: fluoroquinolones, QRDR mutations, PFGE

* Corresponding author. Tel: +1-908-707-3465; Fax: +1-908-707-3501; E-mail: tdavies{at}prdus.jnj.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
K. A. Nichol, H. J. Adam, J. A. Karlowsky, G. G. Zhanel, and D. J. Hoban
Increasing Genetic Relatedness of Ciprofloxacin-Resistant Streptococcus pneumoniae Isolated in Canada from 1997 to 2005
Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1190 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. A. Davies, E. Leibovitz, G. J. Noel, D. F. McNeeley, K. Bush, and R. Dagan
Characterization and Dynamics of Middle Ear Fluid and Nasopharyngeal Isolates of Streptococcus pneumoniae from 12 Children Treated with Levofloxacin
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 378 - 381.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J.-W. Decousser, I. Methlouthi, P. Pina, A. Collignon, P. Allouch, and on behalf of the ColBVH Study Group
New Real-Time PCR Assay Using Locked Nucleic Acid Probes To Assess Prevalence of ParC Mutations in Fluoroquinolone-Susceptible Streptococcus pneumoniae Isolates from France
Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1594 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. A. Davies, Y. C. Yee, R. Goldschmidt, K. Bush, D. F. Sahm, and A. Evangelista
Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003)
J. Antimicrob. Chemother., March 1, 2006; 57(3): 437 - 442.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. A. Davies, K. Bush, D. Sahm, and A. Evangelista
Predominance of 23S rRNA Mutants among Non-Erm, Non-Mef Macrolide-Resistant Clinical Isolates of Streptococcus pneumoniae Collected in the United States in 1999-2000
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 3031 - 3033.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. Korzheva, T. A. Davies, and R. Goldschmidt
Novel Ser79Leu and Ser81Ile Substitutions in the Quinolone Resistance-Determining Regions of ParC Topoisomerase IV and GyrA DNA Gyrase Subunits from Recent Fluoroquinolone-Resistant Streptococcus pneumoniae Clinical Isolates
Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2479 - 2486.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Sadowy, R. Izdebski, A. Skoczynska, M. Gniadkowski, and W. Hryniewicz
High Genetic Diversity of Ciprofloxacin-Nonsusceptible Isolates of Streptococcus pneumoniae in Poland
Antimicrob. Agents Chemother., May 1, 2005; 49(5): 2126 - 2129.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. R. M. Jimenez, J. L. M. Bellido, and J. A. Garcia Rodriguez
Risk Factors Associated with Colonization by Pneumococci with Reduced Susceptibility to Fluoroquinolones in Adult Outpatients
J. Clin. Microbiol., March 1, 2005; 43(3): 1193 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
J. H. Jorgensen, S. A. Crawford, L. M. McElmeel, and C. G. Whitney
Detection of Resistance to Gatifloxacin and Moxifloxacin in Streptococcus pneumoniae with the VITEK 2 Instrument
J. Clin. Microbiol., December 1, 2004; 42(12): 5928 - 5930.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. D. Brown, D. J. Farrell, and I. Morrissey
Prevalence and Molecular Analysis of Macrolide and Fluoroquinolone Resistance among Isolates of Streptococcus pneumoniae Collected during the 2000-2001 PROTEKT US Study
J. Clin. Microbiol., November 1, 2004; 42(11): 4980 - 4987.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. W. R. Pletz, L. McGee, J. Jorgensen, B. Beall, R. R. Facklam, C. G. Whitney, and K. P. Klugman
Levofloxacin-Resistant Invasive Streptococcus pneumoniae in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3491 - 3497.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. S. Almer, J. B. Hoffrage, E. L. Keller, R. K. Flamm, and V. D. Shortridge
In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms
Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2771 - 2777.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
I. Morrissey and G. Tillotson
Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae
J. Antimicrob. Chemother., February 1, 2004; 53(2): 144 - 148.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.